Expanding Access to Naloxone in the United States

Overview

Journal J Med Toxicol

Publisher Springer

Specialty Toxicology

Date 2014 Oct 16

PMID 25316516

Citations 17

Authors

Suzanne Doyon

Steven E Aks

Scott Schaeffer

Affiliations

Soon will be listed here.

Citing Articles

Opioid overdose prevention education in Texas during the COVID-19 pandemic.

Mathias C, Cavazos D, McGlothen-Bell K, Crawford A, Flowers-Joseph B, Wang Z Harm Reduct J. 2023; 20(1):37.

PMID: 36964600 PMC: 10037395. DOI: 10.1186/s12954-023-00769-y.

Medical Student Screening for Naloxone Eligibility in the Emergency Department: A Value-Added Role to Fight the Opioid Epidemic.

Moore P, Cheema N, Follman S, Celmins L, Scott G, Pho M MedEdPORTAL. 2021; 17:11196.

PMID: 34950768 PMC: 8654700. DOI: 10.15766/mep_2374-8265.11196.

Evaluation of Basic Life Support First Responder Naloxone Administration Protocol Adherence.

Mastenbrook J, Emrick D, Bauler L, Markman J, Koedam T, Fales W Cureus. 2021; 13(10):e18932.

PMID: 34812316 PMC: 8604552. DOI: 10.7759/cureus.18932.

Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk?.

Au V, Rosic T, Sanger N, Hillmer A, Chawar C, Worster A Harm Reduct J. 2021; 18(1):71.

PMID: 34238301 PMC: 8265117. DOI: 10.1186/s12954-021-00521-4.

Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.

Moustaqim-Barrette A, Dhillon D, Ng J, Sundvick K, Ali F, Elton-Marshall T BMC Public Health. 2021; 21(1):597.

PMID: 33771150 PMC: 8004425. DOI: 10.1186/s12889-021-10497-2.

References

Piper T, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A . Evaluation of a naloxone distribution and administration program in New York City. Subst Use Misuse. 2008; 43(7):858-70. DOI: 10.1080/10826080701801261. View

Wermeling D . A response to the opioid overdose epidemic: naloxone nasal spray. Drug Deliv Transl Res. 2013; 3(1):63-74. PMC: 3668569. DOI: 10.1007/s13346-012-0092-0. View

Osterwalder J . Naloxone--for intoxications with intravenous heroin and heroin mixtures--harmless or hazardous? A prospective clinical study. J Toxicol Clin Toxicol. 1996; 34(4):409-16. DOI: 10.3109/15563659609013811. View

Merigian K . Cocaine-induced ventricular arrhythmias and rapid atrial fibrillation temporally related to naloxone administration. Am J Emerg Med. 1993; 11(1):96-7. DOI: 10.1016/0735-6757(93)90074-l. View

Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H, Ozonoff A . Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014; 14:297. PMC: 4004504. DOI: 10.1186/1471-2458-14-297. View

Jones C, Mack K, Paulozzi L . Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309(7):657-9. DOI: 10.1001/jama.2013.272. View

Goklany I . From precautionary principle to risk-risk analysis. Nat Biotechnol. 2002; 20(11):1075. DOI: 10.1038/nbt1102-1075. View

Walley A, Xuan Z, Hackman H, Quinn E, Doe-Simkins M, Sorensen-Alawad A . Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013; 346:f174. PMC: 4688551. DOI: 10.1136/bmj.f174. View

Tobin K, Sherman S, Beilenson P, Welsh C, Latkin C . Evaluation of the Staying Alive programme: training injection drug users to properly administer naloxone and save lives. Int J Drug Policy. 2008; 20(2):131-6. DOI: 10.1016/j.drugpo.2008.03.002. View

10.

Strang J, Powis B, Best D, Vingoe L, Griffiths P, Taylor C . Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction. 1999; 94(2):199-204. DOI: 10.1046/j.1360-0443.1999.9421993.x. View

11.

Kelly A, Koutsogiannis Z . Intranasal naloxone for life threatening opioid toxicity. Emerg Med J. 2002; 19(4):375. PMC: 1725919. DOI: 10.1136/emj.19.4.375. View

12.

Doe-Simkins M, Walley A, Epstein A, Moyer P . Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health. 2009; 99(5):788-91. PMC: 2667836. DOI: 10.2105/AJPH.2008.146647. View

13.

Leece P, Orkin A . Opioid overdose fatality prevention. JAMA. 2013; 309(9):873-4. DOI: 10.1001/jama.2013.375. View

14.

Albert S, Brason 2nd F, Sanford C, Dasgupta N, Graham J, Lovette B . Project Lazarus: community-based overdose prevention in rural North Carolina. Pain Med. 2011; 12 Suppl 2:S77-85. DOI: 10.1111/j.1526-4637.2011.01128.x. View

15.

Lagu T, Anderson B, Stein M . Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat. 2006; 30(2):129-33. DOI: 10.1016/j.jsat.2005.05.010. View

16.

. Community-based opioid overdose prevention programs providing naloxone - United States, 2010. MMWR Morb Mortal Wkly Rep. 2012; 61(6):101-5. PMC: 4378715. View

17.

Vilke G, Sloane C, Smith A, Chan T . Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med. 2003; 10(8):893-6. DOI: 10.1111/j.1553-2712.2003.tb00636.x. View

18.

Wolfe T, Braude D . Intranasal medication delivery for children: a brief review and update. Pediatrics. 2010; 126(3):532-7. DOI: 10.1542/peds.2010-0616. View

19.

Dietze P, Cantwell K, Burgess S . Bystander resuscitation attempts at heroin overdose: does it improve outcomes?. Drug Alcohol Depend. 2002; 67(2):213-8. DOI: 10.1016/s0376-8716(02)00063-7. View

20.

Wampler D, Molina D, McManus J, Laws P, Manifold C . No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care. 2011; 15(3):320-4. DOI: 10.3109/10903127.2011.569854. View